MedTech Acquisition Profit Margin

The latest profit margin for MTAC is -130.17% as of June 2026. That compares with -90.82% in the prior-year period — down 43.3% year over year. That is below the sector sector average of 13.78%. Investors often review this figure alongside MedTech Acquisition's historical trend and sector peers before judging valuation or financial health.

Over the past year, MTAC's profit margin moved from -90.82% to -130.17% — a 43.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in MedTech Acquisition's valuation or profitability profile.

Against its sector companies, MTAC currently prints -130.17% for profit margin, while the sector average sits near 13.78%. That is roughly 1044.8% below the sector mean. Large gaps often invite a closer look at MedTech Acquisition's growth, margins, and balance sheet.

Profit Margin shows how effectively MedTech Acquisition converts resources into returns. At -130.17%, MTAC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -90.82% in the prior-year period — down 43.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting MTAC's profit margin (-130.17%), review year-over-year change from -90.82%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.